Rescue PTCA complicated by pulmonary artery rupture after tPA and abciximab.
Since the introduction of pulmonary artery catheterization for hemodynamic monitoring, several complications associated with its use have been described. Pulmonary artery rupture is an infrequent complication of flow-directed pulmonary artery catheters. We report a case of pulmonary artery rupture complicating rescue PTCA in the presence of systemic platelet inhibition with abciximab (Reopro), anticoagulation, and thrombolytic therapy. With the increasing use of these medications in patients undergoing acute coronary interventions, particularly those patients requiring hemodynamic monitoring, this uncommon but potentially fatal complication may be seen more frequently.
Chadow
H L
HL
Department of Medicine, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
Gaba
M K
MK
Safi
A
A
Afflu
E
E
Feit
A
A
D000077284:Abciximab; D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000209:etiology; D017809:Fatal Outcome; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D011651:Pulmonary Artery / Q000293:injuries*; D012421:Rupture; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010959:Tissue Plasminogen Activator; D000077284:Abciximab